Author + information
- Hiroyoshi Mori,
- Dheeraj Atmakuri,
- Robert Kutys,
- Ryan Braumann,
- Sho Torii,
- Maria Romero,
- Emanuel Harari,
- Renu Virmani and
- Aloke Finn
Background: Everolimus-eluting stents (EES, Xience®, Abbott Vascular) has been shown to be clinically superior to other Drug-eluting stents(DES) and bare metal stents (BMS). Although we have previously published pathological features of EES, in the majority of cases the stent implantation duration was < 1 years. The aim of this study was to determine the very late complication of EES in implants > 1 year.
Methods: From our stent registry, a total of 39 EES lesions from 30 cases had an implant duration of ≥ 1years and were compared to matched BMS (Vision®, Abbott vascular, 28 lesions) and sirolimus-eluting stent (SES, Cypher®, Johnson & Johnson, 36 lesions). Stented coronary segments were embedded in plastic blocks, cut at 3mm interval, and sections 4 to 6 microns were stained with H&E and Movat pentachrome.
Results: There were no difference in the indication and the duration for stent implantation. Target lesion failures was the lowest in EES than in SES and BMS (20%, 38%, 48%, respectively, p=0.04). Stent thrombosis was the least in EES compared to SES and BMS (5%, 22%, 17%, respectively). Neointimal thickeness was significantly less in EES and SES than BMS(P<0.01, Table). Inflammation score and percent struts with giant cells were the least in EES followed by BMS and SES. Prevalence of neoatheroscleosis was significantly higher in EES and SES vs. BMS (43%, 59%, 21%, respectively, P<0.01).
Conclusions: EES showed less inflammation and target lesion failure than SES or BMS in implants >1 year in duration.
Poster Contributions Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Coronary Intervention: Drug Eluting Stent & Scaffolds
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1240-138
- 2017 American College of Cardiology Foundation